Clinical Trial

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Study acronym: TREG108
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-06-15; most recent amendment 2025-04-10.
Status change: Not Yet Recruiting → Recruiting 2022-12-13
Trial Details
NCT Number NCT05423691
Lead Sponsor Cellenkos, Inc.
Conditions Myelofibrosis
Enrollment 24 participants
Start Date 2022-12-27
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-13